{
    "ticker": "KZIA",
    "name": "Kazia Therapeutics Limited",
    "description": "Kazia Therapeutics Limited is an oncology-focused biotechnology company based in Australia, dedicated to the development of innovative therapies for cancer treatment. Founded in 2005, Kazia is committed to improving patient outcomes through the advancement of new drugs and therapies. The company's lead product candidate, GDC-0084, is designed to treat glioblastoma, an aggressive form of brain cancer, and is currently undergoing clinical trials. Kazia's research pipeline also includes multiple preclinical and clinical-stage candidates targeting various cancer types, including breast cancer and other solid tumors. With a robust intellectual property portfolio and a team of experienced scientists and industry professionals, Kazia aims to address significant unmet medical needs in oncology. The company's mission is to transform the treatment landscape for cancer patients by bringing forward effective and safe therapies, thereby improving quality of life and survival rates. Kazia collaborates with leading research institutions and engages in partnerships to accelerate drug development processes. Through innovation and commitment to scientific excellence, Kazia is poised to make a meaningful impact in the field of cancer therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Sydney, Australia",
    "founded": "2005",
    "website": "https://www.kaziatherapeutics.com",
    "ceo": "James Garner",
    "social_media": {
        "twitter": "https://twitter.com/KaziaThera",
        "linkedin": "https://www.linkedin.com/company/kazia-therapeutics/"
    },
    "investor_relations": "https://www.kaziatherapeutics.com/investors",
    "key_executives": [
        {
            "name": "James Garner",
            "position": "CEO"
        },
        {
            "name": "Dr. David McIntyre",
            "position": "CSO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "GDC-0084",
                "Cantrixil"
            ]
        },
        {
            "category": "Preclinical Candidates",
            "products": [
                "KAZ-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Kazia Therapeutics Limited | Innovative Cancer Therapies",
        "meta_description": "Explore Kazia Therapeutics Limited, an oncology-focused biotechnology company dedicated to developing innovative cancer treatments. Learn about our lead products and research pipeline.",
        "keywords": [
            "Kazia Therapeutics",
            "oncology",
            "cancer treatment",
            "biotechnology",
            "GDC-0084",
            "glioblastoma"
        ]
    },
    "faq": [
        {
            "question": "What does Kazia Therapeutics specialize in?",
            "answer": "Kazia Therapeutics specializes in developing innovative therapies for cancer treatment."
        },
        {
            "question": "What is Kazia's lead product candidate?",
            "answer": "Kazia's lead product candidate is GDC-0084, aimed at treating glioblastoma."
        },
        {
            "question": "Where is Kazia Therapeutics headquartered?",
            "answer": "Kazia Therapeutics is headquartered in Sydney, Australia."
        },
        {
            "question": "When was Kazia founded?",
            "answer": "Kazia Therapeutics was founded in 2005."
        }
    ],
    "competitors": [
        "AVEO",
        "CLDX",
        "IMMP",
        "TGTX"
    ],
    "related_stocks": [
        "BMY",
        "MRNA",
        "GILD",
        "NVS"
    ]
}